RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SAGE Therapeutics Stock

SAGE Therapeutics ROA 2024

SAGE Therapeutics ROA

-0.61

Ticker

SAGE

ISIN

US78667J1088

WKN

A117WF

In 2024, SAGE Therapeutics's return on assets (ROA) was -0.61, a 56.25% increase from the -0.39 ROA in the previous year.

SAGE Therapeutics Aktienanalyse

What does SAGE Therapeutics do?

SAGE Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding SAGE Therapeutics's Return on Assets (ROA)

SAGE Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing SAGE Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider SAGE Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in SAGE Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about SAGE Therapeutics stock

What is the Return on Assets (ROA) of SAGE Therapeutics this year?

The Return on Assets (ROA) of SAGE Therapeutics is -0.61 undefined this year.

What was the ROA of SAGE Therapeutics compared to the previous year?

The ROA of SAGE Therapeutics has increased by 56.25% compared to the previous year.

What consequences do high ROA have for investors of SAGE Therapeutics?

A high ROA is advantageous for investors of SAGE Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in SAGE Therapeutics?

A low ROA can be unfavorable for investors of SAGE Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of SAGE Therapeutics affect the company?

An increase in ROA of SAGE Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of SAGE Therapeutics impact the company?

A reduction in the ROA of SAGE Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of SAGE Therapeutics?

Some factors that can influence the ROA of SAGE Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of SAGE Therapeutics important for investors?

The ROA of SAGE Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can SAGE Therapeutics take to improve ROA?

To improve ROA, SAGE Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does SAGE Therapeutics pay?

Over the past 12 months, SAGE Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SAGE Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of SAGE Therapeutics?

The current dividend yield of SAGE Therapeutics is .

When does SAGE Therapeutics pay dividends?

SAGE Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SAGE Therapeutics?

SAGE Therapeutics paid dividends every year for the past 0 years.

What is the dividend of SAGE Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is SAGE Therapeutics located?

SAGE Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von SAGE Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SAGE Therapeutics from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did SAGE Therapeutics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of SAGE Therapeutics in the year 2023?

In the year 2023, SAGE Therapeutics distributed 0 USD as dividends.

In which currency does SAGE Therapeutics pay out the dividend?

The dividends of SAGE Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SAGE Therapeutics

Our stock analysis for SAGE Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SAGE Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.